BioCentury
ARTICLE | Company News

Plethora, Shionogi deal

September 2, 2013 7:00 AM UTC

Shionogi's Sciele Pharma Inc. subsidiary granted Plethora regulatory and commercialization rights to PSD502 in North and South America, Japan, Korea, China and Taiwan under an amended 2007 deal. Plethora now has rights to PSD502 worldwide. Plethora plans to submit an NDA to FDA for the product to treat premature ejaculation in 1H14. In 2012, Plethora submitted an MAA to EMA for the topical analgesic spray containing lidocaine and prilocaine. The company expects a decision on the MAA by year end (see BioCentury, May 28, 2007 & July 16, 2012). ...